Migraine Drugs Market Size, Share, Trends, Analysis To 2032

Migraine Drugs Market Insights

According to the report published by Zion Market Research, the global Migraine Drugs Market size was valued at USD 57.85 Billion in 2023 and is predicted to reach USD 163.03 Billion by the end of 2032. The market is expected to grow with a CAGR of 12.2% during the forecast period. The report analyzes the global Migraine Drugs Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Migraine Drugs industry.

Request Free Sample

Global Migraine Drugs Market: Overview

About 12–14% of people around the world suffer from a Migraine; it is a type of a headache. According to regional and international rules, migraine is classified by the nature of the attack and its frequency into a chronic migraine and episodic migraine. Prophylactic and abortive are 2 treatments available for the relief of this headache type. Prophylactic treatment is offered to patients suffering from a chronic migraine in order to avoid migraine attacks utilizing medications like topiramate, botulinum toxin, and others. Abortive treatment is offered to terminate severe migraine attack and includes medication like ergot alkaloids, triptans, and others.

Global Migraine Drugs Market: Growth Factors

The increasing awareness regarding a migraine and various options available for its treatment are the major factors boosting the growth of the global migraine drugs market. A number of organizations including the American Headache and Migraine Association are taking efforts to spread awareness about a migraine and hence coming up with programs and providing support to patients so as to spread awareness regarding the disease and further disorders related to a headache. Due to the increasing number of migraine incidences and rising number of unmet needs in the global migraine drugs market, a number of companies are planning to invest in the migraine drugs R&D. This, in turn, is anticipated to propel the global migraine drugs market growth in the near future.

Request Free Sample

Global Migraine Drugs Market: Segmentation

The global migraine drug market is segmented on the basis of treatment type, route of administration, and distribution channel.

On the basis of treatment type, the global migraine drugs market is segmented as prophylactic and abortive.

The prophylactic treatment segment is further sub-segmented as topiramate, botulinum toxin, and others. The abortive treatment segment is further sub-segmented as ergot alkaloids, triptans, and others.

On the basis of route of administration, the global market is classified as injectable, oral, and others.

The others segment is further sub-segmented as transdermal patches and nasal sprays.

On the basis of the distribution channel, the global migraine drugs market is diversified as hospital pharmacies, retail pharmacies, and others.

Migraine Drugs Market: Report Scope

Global Migraine Drugs Market: Regional Analysis

Asia Pacific is anticipated to dominate the global migraine drugs market and is further expected to continue this trend in the near future. This high growth is mainly owing to the increasing number of people suffering from migraines and rising public awareness of the disease in this region. In addition, China and India are the major developing countries contributing to the global migraine drugs market growth in the Asia Pacific region; this is mainly due to the high occurrence of migraines in these countries. Rising focus on niche products and their launches, along with high penetration of novel drug manufacturers, will further have a positive impact on the growth of the global migraine drugs market in the near future.

Global Migraine Drugs Market: Competitive Players

Some of the major players in the global migraine drugs market include

• Endo
• Allergan
• Impax Laboratories
• Glaxo Smith Kline
• Astellas
• Amgen
• Bayer
• AstraZeneca
• Dr. Reddy's Laboratories
• Zogenix
• CoLucid
• Eli Lilly
• Eisai
• IntelGenx
• Ethypharm
• Klaria.

Other key players dominating the global market are

• Johnson & Johnson
• Luitpold Pharmaceuticals
• Kowa Pharmaceuticals America
• Merck
• Meda
• Pfizer
• OptiNose
• Raptor
• Pozen
• SUDA
• RedHill
• TG Therapeutics
• Teva
• Winston Pharmaceuticals
• NValeant.

The Global Migraine Drugs Market segments are as follows:

By Treatment Type

• prophylactic
• abortive.

By Route Of Administration

• injectable
• oral
• others.

By Distribution Channel

• hospital pharmacies
• retail pharmacies
• others.

Global Migraine Drugs Market: Regional Segment Analysis

• North America
  • The U.S.
• Europe
  • The UK
  • France
  • Germany
• The Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

What Reports Provide

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonies to companies in order to fortify their foothold in the market.